SG149685A1 - Polymer conjugates of neublastin and methods of using same - Google Patents
Polymer conjugates of neublastin and methods of using sameInfo
- Publication number
- SG149685A1 SG149685A1 SG200504719-6A SG2005047196A SG149685A1 SG 149685 A1 SG149685 A1 SG 149685A1 SG 2005047196 A SG2005047196 A SG 2005047196A SG 149685 A1 SG149685 A1 SG 149685A1
- Authority
- SG
- Singapore
- Prior art keywords
- neublastin
- methods
- same
- polymer conjugates
- conjugates
- Prior art date
Links
- 102100026376 Artemin Human genes 0.000 title abstract 5
- 101000785776 Homo sapiens Artemin Proteins 0.000 title abstract 3
- 229920000642 polymer Polymers 0.000 title abstract 3
- 230000002035 prolonged effect Effects 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 125000003827 glycol group Chemical group 0.000 abstract 1
- 229920001515 polyalkylene glycol Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26607101P | 2001-02-01 | 2001-02-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG149685A1 true SG149685A1 (en) | 2009-02-27 |
Family
ID=23013042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG200504719-6A SG149685A1 (en) | 2001-02-01 | 2002-01-25 | Polymer conjugates of neublastin and methods of using same |
Country Status (36)
| Country | Link |
|---|---|
| EP (2) | EP1355936B1 (ru) |
| JP (2) | JP4259868B2 (ru) |
| KR (2) | KR100960063B1 (ru) |
| CN (1) | CN1500095B (ru) |
| AR (1) | AR035077A1 (ru) |
| AT (1) | ATE365748T1 (ru) |
| AU (1) | AU2002247037B2 (ru) |
| BG (1) | BG66393B1 (ru) |
| BR (1) | BR0206852A (ru) |
| CA (1) | CA2436407C (ru) |
| CY (1) | CY1106886T1 (ru) |
| CZ (1) | CZ20032080A3 (ru) |
| DE (1) | DE60220879T2 (ru) |
| DK (1) | DK1355936T3 (ru) |
| EA (1) | EA009771B1 (ru) |
| EE (1) | EE05537B1 (ru) |
| ES (1) | ES2289091T3 (ru) |
| GE (1) | GEP20063916B (ru) |
| HK (1) | HK1057759A1 (ru) |
| HU (1) | HU228973B1 (ru) |
| IL (2) | IL156941A0 (ru) |
| IS (1) | IS2867B (ru) |
| MX (1) | MXPA03006805A (ru) |
| MY (1) | MY143685A (ru) |
| NO (1) | NO332150B1 (ru) |
| NZ (1) | NZ527863A (ru) |
| PL (1) | PL211162B1 (ru) |
| PT (1) | PT1355936E (ru) |
| RS (1) | RS50857B (ru) |
| SG (1) | SG149685A1 (ru) |
| SI (1) | SI1355936T1 (ru) |
| SK (1) | SK288123B6 (ru) |
| TR (1) | TR200301208T2 (ru) |
| UA (2) | UA100967C2 (ru) |
| WO (1) | WO2002060929A2 (ru) |
| ZA (1) | ZA200305733B (ru) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
| WO2002060929A2 (en) * | 2001-02-01 | 2002-08-08 | Biogen, Inc. | Polymer conjugates of neublastin and methods of using same |
| US7276580B2 (en) | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
| EP1395279B1 (en) * | 2001-03-28 | 2011-10-05 | Biogen Idec MA Inc. | Use of neublastin polypeptides for treating neuropathic pain |
| EP3669887A1 (en) * | 2002-01-18 | 2020-06-24 | Biogen MA Inc. | Polyalkylene polymer compounds and uses thereof |
| CN101166753A (zh) * | 2003-01-31 | 2008-04-23 | 比奥根艾迪克Ma公司 | 突变神经胚素的聚合物偶联物 |
| ES2479942T3 (es) | 2003-04-18 | 2014-07-25 | Biogen Idec Ma Inc. | Neublastina glucosilada conjugada con polímero |
| ATE423134T1 (de) * | 2003-06-10 | 2009-03-15 | Nsgene As | Verbesserte sezernierung von neublastin |
| US7598059B2 (en) | 2003-10-02 | 2009-10-06 | Biogen Idec Ma Inc. | Neublastin expression constructs |
| AU2005277227B2 (en) * | 2004-08-19 | 2011-10-06 | Biogen Ma Inc. | Refolding transforming growth factor beta family proteins |
| RS51453B (en) | 2004-08-19 | 2011-04-30 | Biogen Idec Ma Inc. | NEUBLASTIN |
| TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
| WO2007103182A2 (en) * | 2006-03-01 | 2007-09-13 | Biogen Idec Ma Inc. | Compostions and methods for administering gdnf ligand family proteins |
| WO2008031612A1 (en) | 2006-09-15 | 2008-03-20 | Creabilis Therapeutics S.P.A. | Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1 |
| JP5583005B2 (ja) * | 2007-05-01 | 2014-09-03 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 血管新生を増大させるための組成物および方法 |
| BR112014010406A2 (pt) * | 2011-11-02 | 2017-04-25 | Genentech Inc | cromatografia de sobrecarga e eluto |
| RU2488635C1 (ru) * | 2012-03-22 | 2013-07-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития | Способ получения рекомбинантного антиангиогенного полипептида |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000001815A2 (en) * | 1998-07-06 | 2000-01-13 | Nsgene A/S | Neurotrophic factors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6472178B1 (en) * | 1998-02-27 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof |
| US5770577A (en) * | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
| EP1137774A2 (en) * | 1998-12-09 | 2001-10-04 | Amgen Inc. | Grnf4, a gdnf-related neurotrophic factor |
| WO2002060929A2 (en) * | 2001-02-01 | 2002-08-08 | Biogen, Inc. | Polymer conjugates of neublastin and methods of using same |
-
2002
- 2002-01-25 WO PCT/US2002/002319 patent/WO2002060929A2/en active IP Right Grant
- 2002-01-25 BR BR0206852-4A patent/BR0206852A/pt not_active Application Discontinuation
- 2002-01-25 DK DK02714792T patent/DK1355936T3/da active
- 2002-01-25 DE DE60220879T patent/DE60220879T2/de not_active Expired - Lifetime
- 2002-01-25 PT PT02714792T patent/PT1355936E/pt unknown
- 2002-01-25 CN CN028077539A patent/CN1500095B/zh not_active Expired - Fee Related
- 2002-01-25 AR ARP020100279A patent/AR035077A1/es not_active Application Discontinuation
- 2002-01-25 SK SK971-2003A patent/SK288123B6/sk not_active IP Right Cessation
- 2002-01-25 PL PL372101A patent/PL211162B1/pl unknown
- 2002-01-25 TR TR2003/01208T patent/TR200301208T2/xx unknown
- 2002-01-25 ES ES02714792T patent/ES2289091T3/es not_active Expired - Lifetime
- 2002-01-25 NZ NZ527863A patent/NZ527863A/en not_active IP Right Cessation
- 2002-01-25 UA UAA200802148A patent/UA100967C2/ru unknown
- 2002-01-25 CZ CZ20032080A patent/CZ20032080A3/cs unknown
- 2002-01-25 KR KR1020087022638A patent/KR100960063B1/ko not_active IP Right Cessation
- 2002-01-25 EP EP02714792A patent/EP1355936B1/en not_active Expired - Lifetime
- 2002-01-25 IL IL15694102A patent/IL156941A0/xx unknown
- 2002-01-25 AU AU2002247037A patent/AU2002247037B2/en not_active Ceased
- 2002-01-25 MX MXPA03006805A patent/MXPA03006805A/es active IP Right Grant
- 2002-01-25 EP EP07110666A patent/EP1862475A1/en not_active Withdrawn
- 2002-01-25 JP JP2002561497A patent/JP4259868B2/ja not_active Expired - Fee Related
- 2002-01-25 HU HU0500637A patent/HU228973B1/hu not_active IP Right Cessation
- 2002-01-25 EE EEP200300355A patent/EE05537B1/xx not_active IP Right Cessation
- 2002-01-25 CA CA2436407A patent/CA2436407C/en not_active Expired - Fee Related
- 2002-01-25 UA UA2003088104A patent/UA82983C2/ru unknown
- 2002-01-25 SG SG200504719-6A patent/SG149685A1/en unknown
- 2002-01-25 SI SI200230580T patent/SI1355936T1/sl unknown
- 2002-01-25 EA EA200300852A patent/EA009771B1/ru not_active IP Right Cessation
- 2002-01-25 RS YUP-610/03A patent/RS50857B/sr unknown
- 2002-01-25 GE GE5240A patent/GEP20063916B/en unknown
- 2002-01-25 AT AT02714792T patent/ATE365748T1/de active
- 2002-01-25 KR KR1020037010127A patent/KR100872807B1/ko not_active IP Right Cessation
- 2002-02-04 MY MYPI20020368A patent/MY143685A/en unknown
-
2003
- 2003-07-15 IL IL156941A patent/IL156941A/en not_active IP Right Cessation
- 2003-07-17 IS IS6879A patent/IS2867B/is unknown
- 2003-07-24 ZA ZA2003/05733A patent/ZA200305733B/en unknown
- 2003-08-01 NO NO20033441A patent/NO332150B1/no not_active IP Right Cessation
- 2003-08-19 BG BG108111A patent/BG66393B1/bg unknown
- 2003-11-21 HK HK03108539A patent/HK1057759A1/xx not_active IP Right Cessation
-
2007
- 2007-09-21 CY CY20071101225T patent/CY1106886T1/el unknown
-
2008
- 2008-10-28 JP JP2008277469A patent/JP4423338B2/ja not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000001815A2 (en) * | 1998-07-06 | 2000-01-13 | Nsgene A/S | Neurotrophic factors |
Non-Patent Citations (2)
| Title |
|---|
| BALOH R H ET AL: "ARTEMIN, A NOVEL MEMBER OF THE GDNF LIGAND FAMILY, SUPPORTS PERIPHERAL AND CENTRAL NEURONS AND SIGNALS THROUGH THE GFRALPHA3- RET RECEPTOR COMPLEX" * |
| BALOH ROBERT H ET AL: "Functional mapping of receptor specificity domains of glial cell line-derived neurotrophic factor (GDNF) family ligands and production of GFRalpha1 RET-specific agonists." * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG149685A1 (en) | Polymer conjugates of neublastin and methods of using same | |
| EP1196444B8 (en) | Exendin-4 conjugates and their medical use | |
| LTC2599503I2 (lt) | Interferono beta-1A polimero konjugatai ir jų panaudojimas | |
| AU7761594A (en) | Polyethylene glycols | |
| TR200101867T2 (tr) | CCR5 modülatörleri olarak piperidinler | |
| EP1454138A4 (en) | IMMUNOCYTOKINS WITH MODULATED SELECTIVITY | |
| WO2003049699A3 (en) | Novel monofunctional polyethylene glycol aldehydes | |
| PT1107793E (pt) | Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados | |
| ATE331730T1 (de) | Neue depsipeptid-verbindung | |
| MXPA05008168A (es) | Conjugados de polimero de neublastina mutada. | |
| WO2003040119A8 (fr) | Inhibiteurs de l'angiogenese | |
| AU2002354872A1 (en) | Novel chelating agents and conjugates thereof, their synthesis and use as diagnostic and therapeutic agents |